Loading...
•
Dec 31, 2021
Collegium Q4 2021 Earnings Report
Collegium reported a net loss due to a $38.3 million product revenue adjustment related to returns adjustments, despite efforts to manage costs.
Key Takeaways
Collegium Pharmaceutical reported a net loss for Q4 2021, primarily due to a significant revenue adjustment related to product returns. While the company managed to contain operating expenses, the revenue adjustment significantly impacted the financial results. The company is focused on renegotiating Xtampza ER contracts and diversifying the business through acquisitions, with the BDSI acquisition expected to be transformative.
Total net product revenues decreased to $27.4 million, including a $38.3 million product revenue adjustment.
Xtampza ER net product revenues were $5.3 million, including returns adjustments of $13.8 million.
Nucynta franchise net product revenues were $22.1 million, including returns adjustments of $24.5 million.
Net loss for the quarter was ($25.0) million, or ($0.73) loss per share.
Revenue by Segment
Forward Guidance
Collegium expects total revenues in the range of $315 million to $330 million for 2022. A more detailed outlook will be provided after the closing of the acquisition of BioDelivery Sciences International, Inc. (BDSI), expected late in the first quarter of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...